Antibody-drug conjugates, or ADCs, are monoclonal antibodies that are linked to another drug (“payload”) via a molecular linker. This technology allows selective delivery of the payload, often a cytotoxic drug, to the target cell via receptor internalization.
While still a relatively new modality, ADCs are rapidly gaining popularity. Mylotarg was the first ADC that was approved in 2000 for the treatment of leukemia. By 2024, over 370 ADCs have entered the clinic (Colombo et…
